HOOKIPA Pharma Inc. (HOOK)
NASDAQ: HOOK · IEX Real-Time Price · USD
0.582
-0.047 (-7.43%)
At close: Jul 2, 2024, 4:00 PM
0.589
+0.007 (1.24%)
After-hours: Jul 2, 2024, 7:56 PM EDT
HOOKIPA Pharma Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for HOOKIPA Pharma stock have an average target of 5.00, with a low estimate of 4.00 and a high estimate of 6.00. The average target predicts an increase of 759.70% from the current stock price of 0.58.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for HOOKIPA Pharma stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $5 → $6 | Strong Buy | Maintains | $5 → $6 | +931.64% | Jun 5, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $5 | Buy | Reiterates | $5 | +759.70% | May 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6.5 → $5 | Strong Buy | Maintains | $6.5 → $5 | +759.70% | Apr 26, 2024 |
| RBC Capital | RBC Capital | Buy Reiterates $5 | Buy | Reiterates | $5 | +759.70% | Mar 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6.5 | Strong Buy | Reiterates | $6.5 | +1,017.61% | Mar 25, 2024 |
Financial Forecast
Revenue This Year
54.89M
from 20.13M
Increased by 172.70%
Revenue Next Year
18.82M
from 54.89M
Decreased by -65.72%
EPS This Year
-0.29
from -0.86
EPS Next Year
-0.66
from -0.29
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 76.2M | 26.3M | 15.8M | 112.3M | 305.0M |
| Avg | 54.9M | 18.8M | 8.9M | 68.6M | 203.8M |
| Low | 41.7M | 11.7M | 2.5M | 22.1M | 107.0M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 278.7% | -52.2% | -16.3% | 1,158.0% | 344.6% |
| Avg | 172.7% | -65.7% | -52.6% | 668.5% | 197.1% |
| Low | 107.4% | -78.8% | -87.0% | 147.2% | 55.9% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.16 | -0.51 | -0.67 | -0.43 | 0.28 |
| Avg | -0.29 | -0.66 | -0.78 | -0.51 | 0.14 |
| Low | -0.37 | -0.75 | -0.87 | -0.55 | 0.01 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.